Figure 1From: A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)Treatment of metastatic melanoma with HD IL-2 immunotherapy and targeted agent vemurafenib.Back to article page